Treats benign prostatic hyperplasia (BPH). ANDA 90931, held by Sun Pharmaceutical Industries. Tamsulosin Hydrochloride.
As of Nov 21, 2026, ANDA 90931 (Tamsulosin Hydrochloride), held by Sun Pharmaceutical Industries, was first approved by FDA on Jul 15, 2010, with 5 approved supplements and 0 published complete response letters.
Tamsulosin hydrochloride capsules, USP are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tamsulosin Hydrochloride0.4MG ยท capsule;oral | Tamsulosin Hydrochloride | Discontinued |
| Sep 9, 2019 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Nov 9, 2015 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Nov 9, 2015 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Nov 9, 2015 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Oct 12, 2012 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Jul 15, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters